NERV Minerva Neurosciences, Inc

XNAS 2.31 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

NERV $2.31 —
Key stats
$2.31
52-Week Range
$2.24 – $8.80
YTD
-41.07%
Straddle Price
$2.83
P/C Vol Ratio
0.01
Market Cap
$0.1B
Open
$2.37
Day Range
$2.25 – $2.65
Volume
137,588
Prev Close
$2.40
Fair Value
MODEL: LONG

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)5.12%
Beta vs SPY0.63
Cost of Equity (CAPM)8.27% (VRP-adj)
WACC8.30%
Volatility Risk Premium+221.6pp (IV − HV30)
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon5 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.0B
Return on Equity (TTM)185.3%
Book / Price-185.2%
Quality Score1/6 — cyclical/struggling (5y DCF)
SMA 50$3.76 (Market Anchor value)
SMA 20 / Bollinger Mid$2.93
Bollinger Width / SMA202053.3% (drives anchor stability)
Net Debt$0.0B
Market Cap$0B
Peers used for multiples: ALKS, ARGX, BIIB, EWTX, NBIX, PRAX, PTCT, SRRK
60-Day Conviction
54%
20-Day Fair Value
≈ by Nov 23, 2026
$2.31
α +0.4% rank 94%
conviction
24%
40-Day Fair Value
≈ by Dec 22, 2026
ACTIVE
$2.32
α +0.7% rank 95%
conviction
20%
60-Day Fair Value
≈ by Jan 20, 2027
$2.34
α +1.5% rank 94%
conviction
54%
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0% median 42.7× · 3 peers
Peer EV/EBITDA n/a 0% median 23.0× · 4 peers
Peer P/B n/a 0% median 4.7× · 6 peers
Peer P/S n/a 0% median 4.3× · 4 peers
Market Anchor (SMA50) $3.76 100% stability 77% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-10-23 · updated
About
Industry (SIC)
PHARMACEUTICAL PREPARATIONS (2834) · industry map
Exchange
XNAS
Market Cap
$0.1B
Employees
7
List Date
2014-07-01
CIK
0001598646
Next Earnings
2026-11-04
EPS Forecast
($0.14) (1 est.)
Headquarters
Burlington, MA
Homepage
https://www.minervaneurosciences.com

Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'21'22'23'24'25'26Avg
Jan34.03%-10.27%58.28%37.40%0.43%3.57%20.57%
Feb-8.55%-11.72%-7.30%-69.13%-25.94%41.03%-13.60%
Mar-7.01%20.20%-24.17%-1.90%11.11%-12.68%-2.41%
Apr-19.87%-41.44%68.72%-6.72%7.75%15.54%4.00%
May19.43%-19.98%58.78%6.25%-9.41%-19.11%5.99%
Jun-21.89%-1.49%42.15%10.38%10.26%14.67%9.01%
Jul-21.37%-25.35%4.28%-6.09%11.98%-25.33%-10.31%
Aug0.00%337.21%-19.36%-8.67%23.40%14.86%57.91%
Sep-2.25%-4.65%-17.66%0.75%-7.06%-25.22%-9.35%
Oct-11.39%-72.93%-27.95%-10.30%100.00%-28.79%*-8.56%
Nov-33.03%28.26%58.27%-13.93%9.42%--9.80%
Dec-11.47%-55.71%-15.17%-1.70%5.79%---15.65%
Total-65.60%-78.97%183.79%-70.15%164.45%-37.57%15.99%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $2.87
SMA 50: $3.73
SMA 200: $4.95
Current: $2.30
EMA 12: $2.59
EMA 26: $2.98
MACD: -0.3947 | Signal: -0.0155
BEARISH
ADX (14): 33.68
TREND
+DI: 13.33
−DI: 24.90

Momentum Oscillators

RSI (14): 27.33
OVERSOLD
Stoch %K: 9.43
Stoch %D: 12.57
Williams %R: -95.20

Volume & Volatility

BB Upper: $3.77
BB Lower: $1.98
NEUTRAL
OBV: 177,279,157
Vol SMA 20: 119,248
Vol ROC: -28.53%
ATR: $0.27
True Range: $0.40
HV 20: 77.7%
HV 30: 75.8%
HV 60: 82.1%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-24T00:00:00 – 2026-10-23T00:00:00
AI Analysis

LLM Stock Analysis Report: NERV

Executive Summary

Overall Assessment: NEUTRAL (6/10)

Key Drivers:

  • Technical indicators point to a neutral market environment, with no clear trend direction.
  • Low volatility suggests reduced risk.

Primary Risks:

  • Lack of recent news headlines may lead to increased uncertainty and trading range consolidation.
  • Options activity data unavailable, making it difficult to assess potential catalysts or sentiment shifts.

Investment Thesis: NERV is currently experiencing a consolidative phase, with no clear trend direction. The stock's low volatility suggests reduced risk, but the absence of recent news headlines creates uncertainty. A neutral stance is recommended, with an eye on potential breakout levels and support/resistance zones.

Recent News Sentiment Impact: No recent news available; therefore, no sentiment impact can be assessed.

Technical Analysis

Trend Direction: Short-term (1-4 weeks): Consolidative Medium-term (1-3 months): Neutral Long-term (3-12 months): Uptrend

Support/Resistance Levels:

  • SMA 20: $3.91 (support)
  • SMA 50: $4.05 (resistance)
  • Upper Bollinger Band: $4.39 (resistance)

Momentum Signals: RSI (14): 55.65 (neutral) MACD: Bullish signal line crossover above the signal line Bollinger Bands: Neutral, with price near the middle band

Volume Analysis:

  • Volume SMA 20: 39347.75 (increasing)
  • On-Balance Volume (OBV): 170462142.00 (increasing)

News & Sentiment Analysis

Recent Headlines Summary: No recent news available; therefore, no headlines can be summarized.

Sentiment Assessment: Neutral sentiment due to lack of recent news headlines.

Catalyst Identification: None available based on current data.

Market Narrative: The absence of recent news headlines creates uncertainty and neutralizes the market narrative.

Risk & Volatility Assessment

Beta Interpretation: Low risk, with a beta value of 0.51 relative to SPY.

Volatility Regime: Current volatility is low, with a stock volatility reading of 1.63.

Options Market Signals: No options data available; therefore, no market signals can be assessed.

Downside Protection: Support levels are present at SMA 20 ($3.91) and lower Bollinger Band ($3.42).

Market Context & Positioning

Sector Performance: NERV is a single stock with no sector performance to assess.

Institutional Activity: No volume or open interest data available; therefore, institutional activity cannot be assessed.

Correlation Analysis: The correlation between NERV and the market (R-squared) is 0.06, indicating low correlation.

Relative Valuation: NERV's current price is within its trading range, with no clear valuation signals.

Key Levels & Action Items

Critical Price Levels:

  • Support: SMA 20 ($3.91)
  • Resistance: SMA 50 ($4.05) and Upper Bollinger Band ($4.39)

Breakout/Breakdown Levels: None available based on current data.

Time-Sensitive Catalysts: Earnings information is available, but no recent news headlines can be analyzed.

Risk Management: Stop-loss levels should be set near the support zone (SMA 20) to manage risk.

Overall, NERV's neutral market environment and low volatility suggest a reduced risk profile. However, the absence of recent news headlines creates uncertainty, making it essential to monitor potential breakout levels and support/resistance zones. A cautious approach is recommended, with an eye on upcoming earnings information and technical developments.

Generated

NERV Options Activity & IV Rank

Volatility Metrics

Current IV: 263.7%
7-DTE IV: —
Expected Move: $2.83
7-DTE Move: $2.83
Days to Exp: 28 (2026-11-20)

Options Flow

Call Volume: 451
Put Volume: 3
P/C Volume: 0.007
BULLISH
Call OI: 459
Put OI: 0
P/C OI: —
Total OI: 459

ATM Options Pricing

ATM Call: $0.38
ATM Put: $2.45
Call %: 16.2%
Put %: 106.1%

Chain Summary

Chain Volume: 459
Chain OI: 465
Last Updated: 10/23/2026
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
as of Oct 23 · No data
30 DTE / 10d —
— pts EXTREME
as of Oct 23 · ATM 170.1% / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$2.83Oct 23
Beta Analysis

Risk Metrics

Beta: 1.5496
Alpha: -55.24%
Correlation: 0.2153
R-Squared: 4.6%
Stock Volatility: 91.8%
Market Volatility: 12.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own NERV
2 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Millennium Management Hedge fund
Izzy Englander
$3.0M
0.00%
#2361 of 3716-24.7%13F
Renaissance Technologies Hedge fund
Jim Simons
$407K
0.00%
#2672 of 3138-18.3%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

NERV Institutional Ownership (13F)

Latest filings — 2026-09-30

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

64 filers46,802,318 shares$261.29M value
# Filer Shares Value % of Total % of Float Period
1 FEDERATED HERMES, INC. 4,670,426 $25.92M 9.92% — 2026-06-30
2 Janus Henderson Group plc 4,294,259 $25.87M 9.90% — 2026-03-31
3 Jupiter Topco LLC 4,386,027 $24.32M 9.31% — 2026-06-30
4 Vivo Capital, LLC 4,322,747 $23.99M 9.18% — 2026-06-30
5 Balyasny Asset Management L.P. 4,257,000 $23.63M 9.04% — 2026-06-30
6 Logos Global Management LP 3,288,777 $18.25M 6.99% — 2026-06-30
7 FARALLON CAPITAL MANAGEMENT, L.L.C. 2,365,000 $13.13M 5.02% — 2026-06-30
8 BlackRock, Inc. Custodian 2,240,578 $12.44M 4.76% — 2026-06-30
9 Ally Bridge Group (NY) LLC 2,175,802 $12.08M 4.62% — 2026-06-30
10 Foresite Capital Management VI LLC 1,985,584 $11.02M 4.22% — 2026-06-30
11 Vanguard Capital Management LLC 1,892,807 $10.51M 4.02% — 2026-06-30
12 Spruce Street Capital LP 1,655,500 $9.19M 3.52% — 2026-06-30
13 ADAGE CAPITAL PARTNERS GP, L.L.C. 1,419,000 $7.88M 3.01% — 2026-06-30
14 Trails Edge Capital Partners, LP 1,419,000 $7.88M 3.01% — 2026-06-30
15 Seven Fleet Capital Management LP 1,001,373 $5.56M 2.13% — 2026-06-30
16 Geode Capital Management, LLC Custodian 974,236 $5.41M 2.07% — 2026-06-30
17 DV EQUITIES, LLC 754,397 $4.19M 1.60% — 2026-06-30
18 ACUTA CAPITAL PARTNERS, LLC 709,500 $3.94M 1.51% — 2026-06-30
19 Millennium Management LLC Custodian 533,602 $2.96M 1.13% — 2026-06-30
20 State Street Corp 424,915 $2.36M 0.90% — 2026-06-30
21 Vanguard Fiduciary Trust Co 302,604 $1.68M 0.64% — 2026-06-30
22 Northern Trust Corp Custodian 292,117 $1.62M 0.62% — 2026-06-30
23 Vanguard Portfolio Management LLC 234,754 $1.30M 0.50% — 2026-06-30
24 Vanguard Group Inc Custodian 252,029 $1.01M 0.39% — 2025-12-31
25 Goldman Sachs Group Inc Custodian 143,954 $798.95K 0.31% — 2026-06-30
# Filer Notional Value % of Total Period
# Filer Notional Value % of Total Period

NERV Insider Trading (Form 4)

Latest: 2026-08-03
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-08-03 Inderjit Kaul Director Grant (A) +12,147 opt — EDGAR
2026-06-05 Inderjit Kaul Director Grant (A) +50,000 opt — EDGAR
2026-06-05 Remy Luthringer CEO Grant (A) +1,690,700 opt — EDGAR
2026-06-05 Frederick W Ahlholm SVP, CFO and Secretary Grant (A) +680,000 opt — EDGAR
2026-06-05 Hans Peter Hasler Director Grant (A) +50,000 opt — EDGAR
2026-06-05 G Jan Van Heek Director Grant (A) +50,000 opt — EDGAR
2026-06-05 Fouzia Laghrissi-Thode Director Grant (A) +50,000 opt — EDGAR
2026-06-05 David Kupfer Director Grant (A) +50,000 opt — EDGAR
2026-04-22 James Joseph O'Connor Chief Business Officer and GC Grant (A) +350,800 opt — EDGAR
2026-04-01 Inderjit Kaul Director Grant (A) +12,169 opt — EDGAR
2025-12-23 Frederick W Ahlholm SVP, CFO and Secretary Grant (A) +500,000 opt — EDGAR
2025-12-23 Inderjit Kaul Director Grant (A) +364,504 opt — EDGAR
2025-12-23 Hans Peter Hasler Director Grant (A) +50,000 opt — EDGAR
2025-12-23 Fouzia Laghrissi-Thode Director Grant (A) +50,000 opt — EDGAR
2025-12-23 Remy Luthringer CEO Grant (A) +2,250,000 opt — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

NERV Insider Holdings

6 insiders · @ $2.30
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
# Insider Role Shares Disclosed Exposure Lifetime OM Net Filings Last Filed
1 Remy Luthringer CEO 184,819 $425.1K -$535.7K 21 2026-06-05
2 Geoff Race President 73,406 $168.8K -$257.6K 19 2025-12-23
3 David Kupfer Director 23,936 $55.1K $1.61M 16 2026-06-05
4 Frederick W Ahlholm SVP, CFO and Secretary 21,098 $48.5K -$557.7K 22 2026-06-05
5 G Jan Van Heek Director 2,542 $5.8K $94.5K 15 2026-06-05
6 Hans Peter Hasler Director 1,250 $2.9K $56.0K 11 2026-06-05
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.

NERV Board & Officers

As of SEC filings through Aug 20, 2026

Directors 6

Officers 5

Changes in the last 10 years (28)
Aug 10, 2026Anthony Aliquo became Chief Accounting Officer
Apr 21, 2026James Joseph O'Connor became Chief Business Officer and GC
Mar 30, 2026The company announced the departure of Geoff Race as President in an SEC filing
Nov 14, 2025Inderjit Kaul became a director
May 29, 2024The company announced the departure of Jeryl L Hilleman from the board in an SEC filing
Jun 27, 2023Boehringer Ingelheim International Gmbh became a 10% owner
Jun 27, 2023Boehringer AG became a 10% owner
May 3, 2023The company announced the departure of William F Doyle from the board in an SEC filing
Dec 14, 2022Frederick W Ahlholm listed as SVP, CFO and Secretary (previously SVP, Chief Accounting Officer) in SEC filings
Aug 16, 2022Barclays Plc reported in an SEC filing no longer being a 10% owner
Aug 8, 2022Barclays Plc became a 10% owner
Feb 18, 2022Geoff Race listed as President (previously EVP, CFO & Cbo) in SEC filings
Jun 26, 2019Index Venture Associates V Ltd reported in an SEC filing no longer being a 10% owner
Jun 26, 2019Index Venture Associates IV Ltd reported in an SEC filing no longer being a 10% owner
Jun 26, 2019Index Venture Associates III Ltd reported in an SEC filing no longer being a 10% owner
Jun 26, 2019(Jersey) SLP Yucca reported in an SEC filing no longer being a 10% owner
Jul 23, 2018Devin Whittemore Smith became SVP and General Counsel
Jul 16, 2018Jeryl L Hilleman became a director
Dec 15, 2017Remy Luthringer listed as CEO (previously President & CEO) in SEC filings
Dec 11, 2017Richard E. Russell became President
Not reported recently (10)
  • Boehringer AG · Last reported as a 10% owner in an SEC filing dated Jul 7, 2023
  • Boehringer Ingelheim International Gmbh · Last reported as a 10% owner in an SEC filing dated Jul 7, 2023
  • Michael Davidson · Last reported as Chief Medical Officer in an SEC filing dated Oct 14, 2020
  • Jay Saoud · Last reported as SVP and Head of R&D in an SEC filing dated Oct 14, 2020
  • Devin Whittemore Smith · Last reported as SVP and General Counsel in an SEC filing dated Oct 14, 2020
  • Richard E. Russell · Last reported as President in an SEC filing dated Aug 17, 2020
  • Marc D Beer · Last reported as a director in an SEC filing dated Feb 2, 2018
  • Mark S. Levine · Last reported as SVP,General Counsel & Sec. in an SEC filing dated Jun 5, 2017
  • Michele Ollier · Last reported as a director in an SEC filing dated Dec 14, 2016
  • Francesco De Rubertis · Last reported as a director in an SEC filing dated Dec 14, 2016
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

NERV Proposed Insider Sales (Form 144)

Latest: 2026-03-31
Last 30d: 0 filings  ·  Last 90d: 0 filings

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2026-03-31 Federated Hermes Kaufmann Fund II, a portfolio of Federated Hermes Insurance Series 10% Stockholder 8,798 $70.4K 2026-03-31 Canaccord Genuity, Inc. — EDGAR
2026-03-31 Federated Hermes Kaufmann Small Cap Fund, a portfolio of Federated Hermes Equity Funds 10% Stockholder 19,838 $158.7K 2026-03-31 Canaccord Genuity, Inc. — EDGAR
2026-03-31 Federated Hermes Kaufmann Fund, a portfolio of Federated Hermes Equity Funds 10% Stockholder 31,808 $254.5K 2026-03-31 Canaccord Genuity, Inc. — EDGAR
2026-03-10 Federated Hermes Kaufmann Fund II, a portfolio of Federated Hermes Insurance Series 10% Stockholder 12,456 $99.6K 2026-03-10 Canaccord Genuity, Inc. — EDGAR
2026-03-10 Federated Hermes Kaufmann Small Cap Fund, a portfolio of Federated Hermes Equity Funds 10% Stockholder 264,615 $2.12M 2026-03-10 Canaccord Genuity, Inc. — EDGAR
2026-03-10 Federated Hermes Kaufmann Fund, a portfolio of Federated Hermes Equity Funds 10% Stockholder 424,278 $3.39M 2026-03-10 Canaccord Genuity, Inc. — EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
18 ETFs hold NERV
18 shown · $10.29M total exposure · 0.00% AUM-weighted avg weight
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $4.7M — 2026-09-30
2 IWM iShares Russell 2000 ETF iShares (BlackRock) 0.00% $1.9M $74.2B 2026-10-22
3 VXF Vanguard Extended Market ETF Vanguard 0.00% $1.7M — 2026-09-30
4 VTWO Vanguard Russell 2000 ETF Vanguard 0.00% $701,530 — 2026-09-30
5 IWO iShares Russell 2000 Growth ETF iShares (BlackRock) 0.00% $532,454 $13.6B 2026-10-22
6 IWC iShares Micro-Cap ETF iShares (BlackRock) 0.02% $265,555 $1.2B 2026-10-22
7 IWN iShares Russell 2000 Value ETF iShares (BlackRock) 0.00% $221,254 $13.9B 2026-10-22
8 VTWG Vanguard Russell 2000 Growth ETF Vanguard 0.01% $85,271 — 2026-09-30
9 QQQS Invesco NASDAQ Future Gen 200 ETF Invesco 0.29% $57,909 — 2026-10-24
10 RSSL Global X Russell 2000 ETF Global X 0.00% $38,258 — 2026-10-23
11 VTWV Vanguard Russell 2000 Value ETF Vanguard 0.00% $32,602 — 2026-09-30
12 VTHR Vanguard Russell 3000 ETF Vanguard 0.00% $11,578 — 2026-09-30
13 IBRN iShares Neuroscience and Healthcare ETF iShares (BlackRock) 0.14% $8,808 $6.3M 2026-10-22
14 ITWO ProShares Russell 2000 High Income ETF ProShares 0.00% $4,756 — 2026-10-23
15 URTY ProShares UltraPro Russell2000 ProShares 0.00% $3,648 — 2026-10-23
16 UWM ProShares Ultra Russell2000 ProShares 0.00% $2,420 — 2026-10-23
17 HDG ProShares Hedge Replication ETF ProShares 0.00% $101 — 2026-10-23
18 RB ProShares Russell 2000 Dynamic Buffer ETF ProShares 0.00% $34 — 2026-10-23
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
—
TTM Revenue
—
TTM Net Income
—
TTM Op. Cash Flow
—
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
-0.54
P/S
—
EV/EBITDA
-2.56
EV/Sales
—
ROE
185.3%
ROA
-415.6%
Div Yield
0.00%
FCF Yield
-22.84%
Debt/Equity
-0.00
Current Ratio
20.14
Market Cap
$114.59M
as of 2026-10-22
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
2.44M
SI % of Float
6.06%
Days to Cover
12.96
Short Vol Ratio
56.7%
Free Float
40.20M
Float %
84.2%
Short interest 2026-09-30 • Short volume 2026-10-23 • Float 2026-08-14